OncoSec's Intratumoral IL-12 In Metastatic Triple Negative Breast Cancer (TNBC) Selected For Oral Poster Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2018

SAN DIEGO, March 15, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that clinical and immunological data from its OMS-I140 clinical trial of ImmunoPulse® IL-12 in patients with metastatic Triple Negative Breast Cancer (TNBC) has been selected as an oral poster presentation at the upcoming American Association of Cancer Research (AACR) Annual Meeting, in Chicago, IL on April 14-18, 2018.

Details of the oral poster presentation are as follows:

Abstract Title: Intratumoral plasmid IL-12 and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer (TNBC) (Abstract #CT022)

Session Title: Phase I Clinical Trials 1

Date and Time: Sunday, April 15, 2018 1:00 PM - 5:00 PM EST

Location: McCormick Place South, Hall A, Poster Section 42

Further details on the poster presentation will be provided in upcoming Company communications. For more information about this conference, please visit: www.aacr.org.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse^®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical trials, ImmunoPulse^® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.

CONTACT

Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
[email protected]

Media Relations:
Janine McCargo / David Schemelia
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
[email protected]
[email protected]

SOURCE OncoSec Medical Incorporated